FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 09 2023
25 09 2023
Historique:
received:
03
04
2023
accepted:
12
09
2023
medline:
4
10
2023
pubmed:
26
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative proteomic strategy. The Olink Proteomics Multiplex panels (Cardiovascular Disease II, III, Cardiometabolic, and Inflammation Target Panels) identified FGF-23 to be the most differentially abundant (more than 2.5-fold) in blood plasma of HF patients with severe RV dysfunction (n = 30) compared to those with preserved RV function (n = 31). A subsequent ELISA-based confirmatory analysis of circulating FGF-23 in a large cohort of patients (n = 344, 72.7% NYHA III/IV, LVEF 22.5%, 54.1% with moderate/severe RV dysfunction), followed by multivariable regression analysis, revealed that the plasma FGF-23 level was most significantly associated with RV dysfunction grade (p = 0.0004) and congestion in the systemic circulation (p = 0.03), but not with LV-ejection fraction (p = 0.69) or estimated glomerular filtration rate (eGFR, p = 0.08). FGF-23 was associated with the degree of RV dysfunction in both sub-cohorts (i.e. in patients with and without congestion, p < 0.0001). The association between FGF-23 and RV-dysfunction remained significant after the adjustment for BNP (p = 0.01). In contrast, when adjusted for BNP, FGF-23 was no longer associated with LV dysfunction (p = 0.59). The Cox proportional hazard model revealed that circulating FGF-23 was significantly associated with adverse outcomes even after adjusting for BNP, LVEF, RV dysfunction grade and eGFR. Circulating FGF-23 is thus a biomarker of right ventricular dysfunction in HFrEF patients regardless of congestion status.
Identifiants
pubmed: 37749114
doi: 10.1038/s41598-023-42558-4
pii: 10.1038/s41598-023-42558-4
pmc: PMC10520041
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16004Informations de copyright
© 2023. Springer Nature Limited.
Références
Circulation. 1997 Jun 17;95(12):2660-7
pubmed: 9193435
Kidney Int. 2012 Oct;82(7):737-47
pubmed: 22622492
Oncotarget. 2016 Oct 4;7(40):64649-64664
pubmed: 27579618
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
Sci Rep. 2017 Sep 12;7(1):11298
pubmed: 28900153
Nephrol Dial Transplant. 2018 Oct 1;33(10):1722-1734
pubmed: 29425341
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Nat Rev Nephrol. 2020 Jan;16(1):7-19
pubmed: 31519999
Sci Rep. 2021 Aug 24;11(1):17136
pubmed: 34429479
Eur J Heart Fail. 2017 Jul;19(7):926-946
pubmed: 28371221
Sci Rep. 2017 May 16;7(1):1993
pubmed: 28512310
Eur Heart J. 2014 Feb;35(7):448-54
pubmed: 24265434
Eur J Heart Fail. 2017 Dec;19(12):1664-1671
pubmed: 28597497
JACC Heart Fail. 2022 Sep;10(9):623-632
pubmed: 36049813
Annu Rev Physiol. 2013;75:503-33
pubmed: 23398153
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
J Card Fail. 2020 Dec;26(12):1100-1105
pubmed: 32687881
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Circ Heart Fail. 2015 Nov;8(6):1059-67
pubmed: 26273098
Clin Chem. 2012 Jan;58(1):127-38
pubmed: 22086968
J Heart Lung Transplant. 2015 Sep;34(9):1211-4
pubmed: 26267742
J Clin Invest. 2011 Nov;121(11):4393-408
pubmed: 21985788
Circ Heart Fail. 2021 Nov;14(11):e008385
pubmed: 34689571
J Bone Miner Res. 2004 Mar;19(3):429-35
pubmed: 15040831
ESC Heart Fail. 2019 Jun;6(3):536-544
pubmed: 30912310
Front Cardiovasc Med. 2023 Aug 04;10:1194174
pubmed: 37600032
Sci Rep. 2018 Aug 17;8(1):12398
pubmed: 30120363